Nature Communications (May 2024)

The STING agonist IMSA101 enhances chimeric antigen receptor T cell function by inducing IL-18 secretion

  • Ugur Uslu,
  • Lijun Sun,
  • Sofia Castelli,
  • Amanda V. Finck,
  • Charles-Antoine Assenmacher,
  • Regina M. Young,
  • Zhijian J. Chen,
  • Carl H. June

DOI
https://doi.org/10.1038/s41467-024-47692-9
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 16

Abstract

Read online

Abstract As a strategy to improve the therapeutic success of chimeric antigen receptor T cells (CART) directed against solid tumors, we here test the combinatorial use of CART and IMSA101, a newly developed stimulator of interferon genes (STING) agonist. In two syngeneic tumor models, improved overall survival is observed when mice are treated with intratumorally administered IMSA101 in addition to intravenous CART infusion. Transcriptomic analyses of CART isolated from tumors show elevated T cell activation, as well as upregulated cytokine pathway signatures, in particular IL-18, in the combination treatment group. Also, higher levels of IL-18 in serum and tumor are detected with IMSA101 treatment. Consistent with this, the use of IL-18 receptor negative CART impair anti-tumor responses in mice receiving combination treatment. In summary, we find that IMSA101 enhances CART function which is facilitated through STING agonist-induced IL-18 secretion.